banner
p38-MAPK inhibitor PD 169316, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ904

p38-MAPK inhibitor PD 169316, Purity ≥98%

Synonym: 152121-53-4; PD 169316; PD-169316; PD169316; 4-(4-(4-Fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl)pyridine; 4-[4-(4-Fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine; 4-(4-Fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole; p38-MAPK inhibitor

  • MDL: MFCD12405019
  • CAS Number: 152121-53-4
  • Compound CID: 4712
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
PD 169316, soluble in DMSO and insoluble in ethanol and water, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates.
Molecular Weight
360.3
Molecular Formula
C20H13FN4O2
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 12 mg/mL (33.3 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
PD 169316 is used to explore the selective inhibition of p38 MAP kinase and its role in cytokine production and inflammation.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0